Clinical trial
A Phase Ib Study of Itacitinib, a JAK1 Inhibitor, in Advanced Hepatocellular Carcinoma
NCT04358185 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Study of Itacitinib, a JAK1 Inhibitor, in Advanced Hepatocellular Carcinoma
- Lead sponsor
- Imperial College London
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 3, 2018
- Completion date
- April 7, 2023
- Enrollment
- 19 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced hepatocellular carcinoma